EMA recommends standard marketing authorisations for Comirnaty and Spikevax COVID-19 vaccines

EMA’s human medicines committee (CHMP) has recommended converting the conditional marketing authorisations of the COVID-19 vaccines Comirnaty (BioNTech/Pfizer’s vaccine) and Spikevax (Moderna’s vaccine) into standard marketing authorisations. These no longer need to be renewed annually. All other obligations for the companies remain in place.

Euro area monthly balance of payments: July 2022

Current account recorded €20 billion deficit in July 2022, down from €4 billion surplus in previous month Current account surplus amounted to €63 billion (0.5% of euro area GDP) in 12 months to July 2022, down from €370 billion (3.1%) one year earlier In financial account, euro area residents’ net acquisitions of non-euro area portfolio investment securities totalled […]